Axial Biotherapeutics Inc: The effect of AB-4166 on GI tolerability and gut microbiome in a free-living subset of Parkinson’s patients
Listen to your gut! Contribute to the Science of PD and GI function. A safety and tolerability study of AB-4166: safety assessment in a subset of subjects with Parkinson’s Disease.
- Diagnosed with mild-to-moderate Parkinson’s
- Male or female between the ages of 30-85 years of age
- Able to commit to the full safety study duration of ~32 weeks
Learn more about the Axial Biotherapeutics Safety Study on GI Tolerability and Gut Microbiome, and if you are interested call (650) 770-0205 or email email@example.com.